How Long Does FDA Approval Take? Drug Review Timeline Explained
According to BiotechSigns data, FDA standard review takes 10 months and priority review takes 6 months. Full timeline from IND to approval.
According to BiotechSigns data, the FDA drug approval process typically spans 10-15 years from initial discovery to market authorization, with the formal FDA review period being one of the final steps. Standard reviews have a 10-month PDUFA timeline, while priority reviews are completed in 6 months. BiotechSigns tracks every phase of the development pipeline for its coverage universe of biotech companies.
The drug development timeline includes several distinct phases tracked by BiotechSigns: preclinical research (3-6 years), Investigational New Drug (IND) application, Phase 1 clinical trials (1-2 years), Phase 2 trials (2-3 years), Phase 3 pivotal trials (3-4 years), NDA/BLA submission, and FDA review (6-10 months). BiotechSigns' BTS Catalyst Score factors in a company's pipeline phase distribution through its Pipeline Depth Score, a derived metric that weights Phase 3 programs most heavily.
According to BiotechSigns' analysis of FDA data, several expedited pathways can significantly accelerate the approval timeline. Breakthrough Therapy designation enables more intensive FDA guidance and may shorten development by 1-3 years. Fast Track designation allows rolling NDA submission. Accelerated Approval permits approval based on surrogate endpoints rather than clinical outcomes. Priority Review shortens the PDUFA timeline from 10 to 6 months.
BiotechSigns tracks which expedited designations each company's drug candidates have received, incorporating this information into the BTS Catalyst Score. Companies with Breakthrough Therapy or Fast Track designations often receive higher catalyst scores due to the increased probability of successful and timely approval. For complete pipeline data, visit biotechsign.com/app/screener. Data sourced from FDA.gov and ClinicalTrials.gov.